EdgarLookup

Iridium Communications Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Iridium Communications Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
13.1%
Profit Margin
Net income ÷ revenue
4.5%
Return on Assets
Net income ÷ assets
4.47x
Debt-to-Equity
Total liabilities ÷ equity
+4.9%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $871.66M Feb 12, 2026
FY2025 Dec 31, 2024 $830.68M Feb 12, 2026
FY2025 Dec 31, 2023 $790.72M Feb 12, 2026
FY2024 Dec 31, 2022 $721.03M Feb 13, 2025
FY2023 Dec 31, 2021 $614.50M Feb 15, 2024
FY2020 Dec 31, 2020 $146.51M Mar 31, 2021
FY2020 Sep 30, 2020 $151.47M Mar 31, 2021
FY2020 Jun 30, 2020 $140.17M Mar 31, 2021
FY2020 Mar 31, 2020 $145.29M Mar 31, 2021
FY2020 Dec 31, 2019 $138.87M Mar 31, 2021

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $871.66M Feb 12, 2026
FY2025 Dec 31, 2024 $830.68M Feb 12, 2026
FY2025 Dec 31, 2023 $790.72M Feb 12, 2026
FY2024 Dec 31, 2022 $721.03M Feb 13, 2025
FY2023 Dec 31, 2021 $614.50M Feb 15, 2024
FY2022 Dec 31, 2020 $583.44M Feb 16, 2023
FY2021 Dec 31, 2019 $560.44M Feb 17, 2022

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $115.47M Feb 22, 2018
FY2017 Sep 30, 2017 $116.55M Feb 22, 2018
FY2017 Jun 30, 2017 $111.60M Feb 22, 2018
FY2017 Mar 31, 2017 $104.43M Feb 22, 2018
FY2017 Dec 31, 2016 $107.45M Feb 22, 2018
FY2017 Sep 30, 2016 $112.79M Feb 22, 2018
FY2017 Jun 30, 2016 $109.20M Feb 22, 2018
FY2017 Mar 31, 2016 $104.20M Feb 22, 2018
FY2016 Dec 31, 2015 $106.42M Feb 23, 2017
FY2016 Sep 30, 2015 $106.03M Feb 23, 2017

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $114.37M Feb 12, 2026
FY2025 Dec 31, 2024 $112.78M Feb 12, 2026
FY2025 Dec 31, 2023 $15.42M Feb 12, 2026
FY2024 Dec 31, 2022 $8.72M Feb 13, 2025
FY2023 Dec 31, 2021 ($9.32M) Feb 15, 2024
FY2020 Dec 31, 2020 ($7.93M) Mar 31, 2021
FY2020 Sep 30, 2020 ($4.01M) Mar 31, 2021
FY2020 Jun 30, 2020 ($12.42M) Mar 31, 2021
FY2020 Mar 31, 2020 ($31.70M) Mar 31, 2021
FY2020 Dec 31, 2019 ($107.86M) Mar 31, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $235.98M Feb 12, 2026
FY2025 Dec 31, 2024 $200.38M Feb 12, 2026
FY2025 Dec 31, 2023 $81.63M Feb 12, 2026
FY2024 Dec 31, 2022 $76.68M Feb 13, 2025
FY2023 Dec 31, 2021 $46.31M Feb 15, 2024
FY2020 Dec 31, 2020 $5.10M Mar 31, 2021
FY2020 Sep 30, 2020 $12.73M Mar 31, 2021
FY2020 Jun 30, 2020 $5.83M Mar 31, 2021
FY2020 Mar 31, 2020 $11.82M Mar 31, 2021
FY2020 Dec 31, 2019 $1.0K Mar 31, 2021

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $19.76M Feb 12, 2026
FY2025 Dec 31, 2024 $28.42M Feb 12, 2026
FY2025 Dec 31, 2023 $20.27M Feb 12, 2026
FY2024 Dec 31, 2022 $16.22M Feb 13, 2025
FY2023 Dec 31, 2021 $11.89M Feb 15, 2024
FY2022 Dec 31, 2020 $12.04M Feb 16, 2023
FY2021 Dec 31, 2019 $14.31M Feb 17, 2022
FY2020 Dec 31, 2018 $22.43M Mar 31, 2021
FY2019 Dec 31, 2017 $15.25M Feb 25, 2020
FY2018 Dec 31, 2016 $16.08M Feb 28, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $157.71M Feb 12, 2026
FY2025 Dec 31, 2024 $168.18M Feb 12, 2026
FY2025 Dec 31, 2023 $143.71M Feb 12, 2026
FY2024 Dec 31, 2022 $123.50M Feb 13, 2025
FY2023 Dec 31, 2021 $100.47M Feb 15, 2024
FY2022 Dec 31, 2020 $90.05M Feb 16, 2023
FY2021 Dec 31, 2019 $93.17M Feb 17, 2022
FY2020 Dec 31, 2018 $97.85M Mar 31, 2021
FY2019 Dec 31, 2017 $84.41M Feb 25, 2020
FY2018 Dec 31, 2016 $82.55M Feb 28, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $400.07M Feb 12, 2026
FY2025 Dec 31, 2024 $375.96M Feb 12, 2026
FY2025 Dec 31, 2023 $314.91M Feb 12, 2026
FY2024 Dec 31, 2022 $344.73M Feb 13, 2025
FY2023 Dec 31, 2021 $302.87M Feb 15, 2024
FY2022 Dec 31, 2020 $249.77M Feb 16, 2023
FY2021 Dec 31, 2019 $198.14M Feb 17, 2022
FY2020 Dec 31, 2018 $263.71M Mar 31, 2021
FY2019 Dec 31, 2017 $259.62M Feb 25, 2020
FY2012 Dec 31, 2012 $174.02M Mar 5, 2013

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $100.28M Feb 12, 2026
FY2025 Dec 31, 2024 $69.89M Feb 12, 2026
FY2025 Dec 31, 2023 $73.49M Feb 12, 2026
FY2024 Dec 31, 2022 $71.27M Feb 13, 2025
FY2023 Dec 31, 2021 $42.15M Feb 15, 2024
FY2022 Dec 31, 2020 $38.69M Feb 16, 2023
FY2021 Dec 31, 2019 $117.82M Feb 17, 2022
FY2020 Dec 31, 2018 $391.39M Mar 31, 2021
FY2019 Dec 31, 2017 $400.11M Feb 25, 2020
FY2018 Dec 31, 2016 $405.69M Feb 28, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.53B Feb 12, 2026
FY2025 Dec 31, 2024 $2.67B Feb 12, 2026
FY2024 Dec 31, 2023 $2.66B Feb 13, 2025
FY2023 Dec 31, 2022 $2.95B Feb 15, 2024
FY2022 Dec 31, 2021 $3.18B Feb 16, 2023
FY2021 Dec 31, 2020 $3.36B Feb 17, 2022
FY2020 Dec 31, 2019 $3.62B Mar 31, 2021
FY2019 Dec 31, 2018 $4.01B Feb 25, 2020
FY2018 Dec 31, 2017 $3.78B Feb 28, 2019
FY2017 Dec 31, 2016 $3.50B Feb 22, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.07B Feb 12, 2026
FY2025 Dec 31, 2024 $2.09B Feb 12, 2026
FY2024 Dec 31, 2023 $1.77B Feb 13, 2025
FY2023 Dec 31, 2022 $1.83B Feb 15, 2024
FY2022 Dec 31, 2021 $1.89B Feb 16, 2023
FY2021 Dec 31, 2020 $1.94B Feb 17, 2022
FY2020 Dec 31, 2019 $2.16B Mar 31, 2021
FY2019 Dec 31, 2018 $2.41B Feb 25, 2020
FY2018 Dec 31, 2017 $2.19B Feb 28, 2019
FY2017 Dec 31, 2016 $2.16B Feb 22, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $462.60M Feb 12, 2026
FY2025 Dec 31, 2024 $576.64M Feb 12, 2026
FY2025 Dec 31, 2023 $888.10M Feb 12, 2026
FY2025 Dec 31, 2022 $1.13B Feb 12, 2026
FY2024 Dec 31, 2021 $1.29B Feb 13, 2025
FY2023 Dec 31, 2020 $1.42B Feb 15, 2024
FY2022 Dec 31, 2019 $1.46B Feb 16, 2023
FY2021 Dec 31, 2018 $1.60B Feb 17, 2022
FY2020 Dec 31, 2017 $1.60B Mar 31, 2021
FY2019 Dec 31, 2016 $1.34B Feb 25, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $98.94M Feb 12, 2026
FY2025 Dec 31, 2024 $98.19M Feb 12, 2026
FY2024 Apr 1, 2024 $98.19M Feb 13, 2025
FY2024 Dec 31, 2023 $0 Feb 13, 2025
FY2018 Dec 31, 2017 $0 Feb 28, 2019
FY2017 Dec 31, 2016 $0 Feb 22, 2018
FY2016 Dec 31, 2015 $0 Feb 23, 2017
FY2015 Dec 31, 2014 $87.04M Feb 25, 2016
FY2014 Dec 31, 2013 $87.04M Feb 26, 2015
FY2013 Dec 31, 2012 $87.04M Mar 4, 2014

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($418.55M) Feb 12, 2026
FY2025 Dec 31, 2024 ($406.09M) Feb 12, 2026
FY2024 Dec 31, 2023 ($235.40M) Feb 13, 2025
FY2023 Dec 31, 2022 ($47.74M) Feb 15, 2024
FY2022 Dec 31, 2021 $140.81M Feb 16, 2023
FY2021 Dec 31, 2020 $275.92M Feb 17, 2022
FY2020 Dec 31, 2019 $331.97M Mar 31, 2021
FY2019 Dec 31, 2018 $501.71M Feb 25, 2020
FY2018 Dec 31, 2017 $518.79M Feb 28, 2019
FY2017 Dec 31, 2016 $288.80M Feb 22, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $96.50M Feb 12, 2026
FY2025 Dec 31, 2024 $93.53M Feb 12, 2026
FY2024 Dec 31, 2023 $71.87M Feb 13, 2025
FY2023 Dec 31, 2022 $168.77M Feb 15, 2024
FY2022 Dec 31, 2021 $320.91M Feb 16, 2023
FY2021 Dec 31, 2020 $237.18M Feb 17, 2022
FY2020 Dec 31, 2019 $223.56M Mar 31, 2021
FY2019 Dec 31, 2018 $273.35M Feb 25, 2020
FY2018 Dec 31, 2017 $285.87M Feb 28, 2019
FY2017 Dec 31, 2016 $371.17M Feb 22, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.76B Feb 12, 2026
FY2025 Dec 31, 2024 $1.76B Feb 12, 2026
FY2024 Dec 31, 2023 $1.47B Feb 13, 2025
FY2023 Dec 31, 2022 $1.47B Feb 15, 2024
FY2021 Dec 31, 2021 $1.58B Feb 17, 2022
FY2020 Dec 31, 2020 $1.60B Mar 31, 2021
FY2019 Dec 31, 2019 $1.77B Feb 25, 2020
FY2018 Dec 31, 2018 $1.83B Feb 28, 2019
FY2017 Dec 31, 2017 $1.62B Feb 22, 2018
FY2016 Dec 31, 2016 $1.80B Feb 23, 2017

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 1 Feb 12, 2026
FY2025 Dec 31, 2024 0 Feb 12, 2026
FY2025 Dec 31, 2023 0 Feb 12, 2026
FY2024 Dec 31, 2022 0 Feb 13, 2025
FY2023 Dec 31, 2021 0 Feb 15, 2024
FY2022 Dec 31, 2020 0 Feb 16, 2023
FY2019 Dec 31, 2019 0 Feb 25, 2020
FY2019 Sep 30, 2019 0 Feb 25, 2020
FY2019 Jun 30, 2019 0 Feb 25, 2020
FY2019 Mar 31, 2019 0 Feb 25, 2020

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 1 Feb 12, 2026
FY2025 Dec 31, 2024 0 Feb 12, 2026
FY2025 Dec 31, 2023 0 Feb 12, 2026
FY2024 Dec 31, 2022 0 Feb 13, 2025
FY2019 Dec 31, 2019 0 Feb 25, 2020
FY2019 Sep 30, 2019 0 Feb 25, 2020
FY2019 Jun 30, 2019 0 Feb 25, 2020
FY2019 Mar 31, 2019 0 Feb 25, 2020
FY2019 Dec 31, 2018 0 Feb 25, 2020
FY2019 Sep 30, 2018 0 Feb 25, 2020

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 110.36M Feb 13, 2025
FY2024 Dec 31, 2023 122.78M Feb 13, 2025
FY2023 Dec 31, 2022 125.90M Feb 15, 2024
FY2022 Dec 31, 2021 131.34M Feb 16, 2023
FY2021 Dec 31, 2020 134.06M Feb 17, 2022
FY2020 Dec 31, 2019 131.63M Mar 31, 2021
FY2019 Dec 31, 2018 112.20M Feb 25, 2020
FY2018 Dec 31, 2017 98.20M Feb 28, 2019
FY2017 Dec 31, 2016 95.88M Feb 22, 2018
FY2016 Dec 31, 2015 95.13M Feb 23, 2017

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $62.85M Feb 12, 2026
FY2025 Dec 31, 2024 $64.74M Feb 12, 2026
FY2025 Dec 31, 2023 $64.77M Feb 12, 2026
FY2024 Dec 31, 2022 $0 Feb 13, 2025
FY2023 Dec 31, 2021 $0 Feb 15, 2024